Tenamfetamine
- Generic Name
- Tenamfetamine
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13NO2
- CAS Number
- 4764-17-4
- Unique Ingredient Identifier
- XJZ28FJ27W
- Background
An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]
Effects of MDMA-like Substances in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: lysine-3,4-methylenedioxyamphetamineOther: Placebo
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 23
- Registration Number
- NCT04847206
- Locations
- 🇨ðŸ‡
University Hospital Basel, Clinical Trial Unit, Basel, BS, Switzerland
Effectiveness of Mass Drug Administration for Reducing Seasonal Malaria Transmission in Zanzibar
Not Applicable
Completed
- Conditions
- Plasmodium InfectionsMalaria
- Interventions
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2017-10-05
- Lead Sponsor
- Ulrika Morris
- Target Recruit Count
- 22500
- Registration Number
- NCT02721186
- Locations
- 🇹🇿
Zanzibar Malaria Elimination Programme, Mwanakwerekwe, Urban District, Zanzibar, Tanzania
Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia
Not Applicable
Completed
- Conditions
- MalariaMalaria, Falciparum
- Interventions
- Drug: Focal MDA with DHAp (Eurartesim)
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- PATH
- Target Recruit Count
- 2430
- Registration Number
- NCT02329301
- Locations
- 🇿🇲
Southern province medical office, Choma, Southern, Zambia
Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]
- First Posted Date
- 2009-01-15
- Last Posted Date
- 2013-05-31
- Target Recruit Count
- 12
- Registration Number
- NCT00823407
- Locations
- 🇺🇸
CPMC Addiction & Pharmacology Research Laboratory (APRL), San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath